Compare
Integrated Biopharma Inc vs Cumberland Pharmaceuticals Inc vs Aquestive Therapeutics, Inc. vs Lexicon Pharmaceuticals, Inc.
| Latest fiscal year | Integrated Biopharma Inc INBP | Cumberland Pharmaceuticals Inc CPIX | Aquestive Therapeutics, Inc. AQST | Lexicon Pharmaceuticals, Inc. LXRX |
|---|---|---|---|---|
| Year ended | 2026-06-30 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $43.87M | $44.52M | $44.55M | $49.80M |
| Revenue growth (YoY) | -19.3% | +17.6% | -22.6% | +60.2% |
| Gross margin | 1.8% | 85.0% (computed) | 58.3% (computed) | n/a |
| Operating margin | -6.2% | -6.3% | -159.5% | -98.2% |
| Net margin | -6.5% | -6.4% | -188.1% | -101.1% |
| Net income | -$2.84M | -$2.84M | -$83.78M | -$50.34M |
| EPS (Diluted) | -$0.09 | -$0.19 | -$0.78 | -$0.14 |
| Operating cash flow | $1.24M | $4.93M | -$52.43M | -$67.85M |
| Free cash flow | $895.0K | $4.83M | -$52.99M | -$67.85M |
| Cash & equivalents | $4.47M | $11.44M | n/a | $34.33M |
| Total assets | $25.34M | $76.82M | $160.43M | $184.99M |
| Total liabilities | $7.67M | $52.28M | $194.09M | $77.45M |
| Shareholders' equity | $17.67M | $24.88M | -$33.66M | $107.54M |
| Return on year-end equity | -16.1% | -11.4% | n/a | -46.8% |
| Shares outstanding | 31.06M | 14.96M | 122.04M | 365.85M |
Revenue, most recent five fiscal years
| Fiscal year | Integrated Biopharma Inc | Cumberland Pharmaceuticals Inc | Aquestive Therapeutics, Inc. | Lexicon Pharmaceuticals, Inc. |
|---|---|---|---|---|
| Latest | $43.87M Ended 2026-06-30 | $44.52M Ended 2025-12-31 | $44.55M Ended 2025-12-31 | $49.80M Ended 2025-12-31 |
| 1 year earlier | $54.35M Ended 2025-06-30 | $37.87M Ended 2024-12-31 | $57.56M Ended 2024-12-31 | $31.08M Ended 2024-12-31 |
| 2 years earlier | $50.32M Ended 2024-06-30 | $39.55M Ended 2023-12-31 | $50.58M Ended 2023-12-31 | $1.20M Ended 2023-12-31 |
| 3 years earlier | $50.67M Ended 2023-06-30 | $42.01M Ended 2022-12-31 | $47.68M Ended 2022-12-31 | $139.0K Ended 2022-12-31 |
| 4 years earlier | $56.25M Ended 2022-06-30 | $35.05M Ended 2021-12-31 | $50.83M Ended 2021-12-31 | $298.0K Ended 2021-12-31 |